CD8A and neoplasm: Imatinib treatment promotes a selective loss of activated Treg cells, but not tumor antigen-specific CD8+ T cells, due to the relatively lower levels of tonic LCK signaling in activated Treg cells, thus rendering them more susceptible to TCR deprivation-induced apoptosis [187].